Skip to main content
Find more clinical trials

Imaging Neurodegeneration With [11C]MPC6827

Start: January 8, 2021
End: September 2025
Enrollment: 40

What Is This Study About?

This pilot study will evaluate the safety and feasibility of [11C]MPC6827 as an imaging tracer to detect the early breakdown of neurons, called neurodegeneration, in people with Alzheimer's disease or amyotrophic lateral sclerosis (ALS). In the first part of the study, up to five healthy volunteers will be injected with a small dose of the tracer followed by positron emission tomography (PET) and computed tomography (CT) full-body imaging scans. Next, up to 30 participants, including healthy volunteers and adults with Alzheimer's and ALS, will be injected with a full dose of the tracer followed by extended imaging with up to two hours of PET-CT scans to assess the body's processing of the tracer over time. Researchers will monitor all participants for safety and any adverse events throughout the study.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Participants must be either:
    • Healthy volunteer with no history or current evidence of brain disease
    • Participant with a diagnosis and receiving treatment for Alzheimer's disease or ALS
  • Women of childbearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to starting the study and for the duration of study participation

Must NOT have:

  • Evidence of brain disease other than Alzheimer's disease or ALS
  • Medications or severe medical condition, disease, or infection that could interfere or make the study unsafe
  • Currently taking any other investigational radiation drugs
  • Women who are pregnant or breastfeeding
  • Unable to tolerate PET scan or CT imaging

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Rodolfo Arevalo, BA

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

New York
Cuimc / Nyp
New York, NY 10032
Recruiting
Rodolfo Arevalo, BA

Who Sponsors This Study?

Lead: Columbia University

Source: ClinicalTrials.gov ID: NCT04575727